Davey B. Daniel
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 28
- Cancer Immunotherapy and Biomarkers 17
- Lung Cancer Research Studies 9
- Cancer Treatment and Pharmacology 3
- Colorectal Cancer Treatments and Studies 2
-
- Lung Cancer Treatments and Mutations 19
- Lung Cancer Diagnosis and Treatment 6
- Co-authors
- Maen Hussein (5 shared papers)Venice Rosalie Archer (2 shared papers)Achim Rittmeyer (2 shared papers)Tania Ochi Lohmann (2 shared papers)Federico Cappuzzo (2 shared papers)Alona Zer (2 shared papers)Steve McCune (3 shared papers)Hans‐Georg Kopp (2 shared papers)
- Journals
- Annals of Oncology (11 papers)Journal of Thoracic Oncology (7 papers)Clinical Lung Cancer (4 papers)Journal of Clinical Oncology (4 papers)The Lancet Oncology (3 papers)
- Partner nations
- United StatesSpainJapan
In The Last Decade
Davey B. Daniel
60 papers receiving 10.6k citations
Davey B. Daniel's Hit Papers
Peers
Comparison fields: 5 of 118
- Oncology 6.1k
- Pulmonary and Respiratory Medicine 4.4k
- Cancer Research 966
- Immunology 1.2k
- Otorhinolaryngology 137
Countries citing papers authored by Davey B. Daniel
This map shows the geographic impact of Davey B. Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davey B. Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davey B. Daniel more than expected).
Fields of papers citing papers by Davey B. Daniel
This network shows the impact of papers produced by Davey B. Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davey B. Daniel. The network helps show where Davey B. Daniel may publish in the future.
Co-authors
The 25 scholars most cited alongside Davey B. Daniel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 3546 |
| 2 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC Hit paper breakdown → | 2018 | 2228 |
| 3 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1337 |
| 4 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 496 |
| 5 | Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Hit paper breakdown → | 2019 | 486 |
| 6 | Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2013 | 410 |
| 7 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC Hit paper breakdown → | 2019 | 343 |
| 8 | 2020 | 170 | |
| 9 | 2020 | 168 | |
| 10 | Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Hit paper breakdown → | 2024 | 159 |
| 11 | 2019 | 153 | |
| 12 | 2019 | 140 | |
| 13 | 2011 | 138 | |
| 14 | 2023 | 100 | |
| 15 | 2017 | 90 | |
| 16 | Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study Hit paper breakdown → | 2024 | 89 |
| 17 | 2020 | 68 | |
| 18 | 1980 | 65 | |
| 19 | 2006 | 59 | |
| 20 | 2021 | 57 |
About Davey B. Daniel
Davey B. Daniel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hematology and Anesthesiology and Pain Medicine, having authored 62 papers that have together received 10.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (19 papers), Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Research Studies (9 papers), Lung Cancer Diagnosis and Treatment (6 papers), Cancer Genomics and Diagnostics (4 papers), Cancer Treatment and Pharmacology (3 papers), Erythropoietin and Anemia Treatment (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (6.1k citations), Pulmonary and Respiratory Medicine (4.4k citations), Cancer Research (966 citations), Immunology (1.2k citations) and Otorhinolaryngology (137 citations). Davey B. Daniel has collaborated with scholars based in United States, Spain and Japan. Frequent co-authors include Maen Hussein, Venice Rosalie Archer, Achim Rittmeyer, Tania Ochi Lohmann, Federico Cappuzzo, Alona Zer, Steve McCune, Hans‐Georg Kopp, Michael McCleod and Howard West. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Clinical Lung Cancer, Journal of Clinical Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.